Clinical trials: Infection and Inflammatory Reaction
Skin Diseases, Infectious
Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections
To compare the safety and the efficacy of tigecycline to vancomycin with aztreonam in treating hospitalized patients with complicated skin and/or skin structure infections.
- Trial name
- NCT00228410
- Testing
- Tigecycline, vancomycin with aztreonam
- Volunteers
- 503 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bacterial Infection
Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
This study evaluates the safety and clinical benefit of MBN-101 administered intraoperatively to osteosynthesis or osteomyelitis sites for patients diagnosed with an orthopedic infection, with or without orthopaedic hardware.
- Trial name
- NCT02436876
- Testing
- MBN-101
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Microbion Corporation
Sepsis
Value of Laboratory Biomarkers in Prediction of Outcome in Septic Patients
Sepsis is defined as a dysregulated host response to infection . Despite ongoing efforts, both the incidence and mortality of sepsis have demonstrated limited reductions over the past years,There are several biomarkers that have…
- Trial name
- NCT06338124
- Testing
- Triglyceride glucose index
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Egymedicalpedia
Sepsis, Hypotension
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
The purpose of this study is to determine whether continued administration of Drotrecogin Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion period - results in a more rapid resolution of…
- Trial name
- NCT00190788
- Testing
- Drotrecogin Alfa (Activated)
- Where
- 2 sites in United States, France
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Candidiasis
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.
- Trial name
- NCT00036179
- Testing
- FK463
- Where
- 23 sites in Austria, France and 6 more
- Volunteers
- 75 people
- Sponsor
- Astellas Pharma Inc
COVID-19
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted…
- Trial name
- NCT04452942
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- EicOsis Human Health Inc.
End Stage Renal Disease
HeRO Vascular Access Device Post Market Procedural Survey Protocol
Post market observational survey of a vascular access device for access-challenged patients. Data collection efforts focused on patient medical and access history and implant procedure results.
- Trial name
- PPS (NCT00889291)
- Volunteers
- 77 people
- Sponsor
- Merit Medical Systems, Inc.
Plaque, Gingivitis
Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study
The objective of this randomized, single-center, examiner-blind, controlled, parallel group, six-month clinical study is to compare the antiplaque/antigingivitis potential of a no-alcohol essential oil containing mouthrinse and…
- Conditions
- Plaque, Gingivitis, Gum Inflammation, Bleeding
- Trial name
- NCT02980497
- Testing
- Listerine Zero Mouthwash (without alcohol), Listerine Antiseptic Mouthwash (with alcohol)
- Where
- Brazil
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Skin Infections
Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection
The purpose of this study is to evaluate the potential effect and safety of two different doses of PZ-601 and to compare this with another antibiotic that is approved by the US Food and Drug Administration (also known as FDA) to…
- Trial name
- NCT00671580
- Testing
- PZ-601, Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 99 people
- Sponsor
- Protez Pharmaceuticals, Inc.
Skin Infections, Bacterial
United States Pharmacovigilence Retapamulin-Prescribing
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the United States (US), retapamulin is approved for the treatment of impetigo in persons nine or more…
- Trial name
- NCT01153880
- Testing
- Retapamulin, Co-prescription of retapamulin and topical mupirocin
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Severe Sepsis, Septic Shock
Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis
The purpose of this study is to determine whether BMS-936559 is safe and has the desired pharmacologic activity in patients who have severe sepsis.
- Trial name
- NCT02576457
- Testing
- BMS-936559
- Where
- 13 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Fever, Cancer
Remote Temperature Monitoring of Patients At Risk for Developing Fever
The purpose of this program is to evaluate remote temperature monitoring in cancer patients at risk of fever and infection due to chemotherapy treatment.
- Conditions
- Fever, Cancer, Remote Patient Monitoring
- Trial name
- NCT06752512
- Testing
- Remote Patient Monitoring
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- AION Biosystems
Sepsis, Disseminated Intravascular Coagulation
Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation
The purpose of this study is to see if ART-123 (recombinant human soluble thrombomodulin) decreases the number of people who die as a result of Disseminated Intravascular Coagulation (DIC) complication of sepsis.
- Trial name
- NCT00487656
- Testing
- ART-123
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 750 people
- Sponsor
- Artisan Pharma, Inc.
Sepsis, COVID-19
SQuISH-COVID: A Pilot Study
This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious…
- Trial name
- NCT04372472
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cytovale, Inc.
HIV Infections, Hepatitis B
ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency
The purpose of this study is to determine the safety and effects in HIV patients of supplementation (4-20 fl. oz. daily) with ProAlgaZyme, a novel fermentation product of a freshwater algae ecosystem, on markers of immune status…
- Conditions
- HIV Infections, Hepatitis B, Dyslipidemia
- Trial name
- NCT00493506
- Testing
- ProAlgaZyme
- Where
- Cameroon
- Volunteers
- 59 people
- Sponsor
- Health Enhancement Products, Inc.
Sepsis
abioSCOPE PSP Reference Range Study; Extension of AB-PSP-003
This is a monocentric, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally…
- Trial name
- AB-PSP-007 (NCT05849935)
- Testing
- abioSCOPE
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Abionic SA
Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
- Trial name
- NCT06981078
- Testing
- Verekitug
- Where
- 242 sites in United States, Argentina and 21 more
- Volunteers
- 666 people
- Sponsor
- Upstream Bio Inc.
Candidemia, Mycoses
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- STRIVE (NCT02734862)
- Testing
- CD101, Caspofungin, Fluconazole
- Where
- 63 sites in United States, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Severe Sepsis, Septic Shock
A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
The two co-primary objectives of this study are to assess in Japanese patients with severe sepsis and/or septic shock: 1) the safety and tolerability of two different doses of intravenous AZD9773 and 2) the PK of AZD9773.
- Trial name
- NCT01144624
- Testing
- AZD9773
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Candidemia
Serial Therapeutic and Antifungal Monitoring Protocol
The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture.
- Trial name
- STAMP (NCT02163889)
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- T2 Biosystems